Cargando…
Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas
Purpose: Loco-regional control and organ preservation are significantly improved with concomitant cisplatin/radiotherapy and are compromised with less than 5% grade 3 nephrotoxicity (creatinine clearance 15–29 mL/min). However, although clinically important, in none of the randomized trials is grade...
Autores principales: | Hoek, Jantien, Bloemendal, Karen M., van der Velden, Lilly-Ann A., van Diessen, Judi N.A., van Werkhoven, Erik, Klop, Willem M.C., Tesselaar, Margot E.T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773744/ https://www.ncbi.nlm.nih.gov/pubmed/26891330 http://dx.doi.org/10.3390/cancers8020021 |
Ejemplares similares
-
Evaluating dose of cisplatin responsible for causing nephrotoxicity
por: Higuchi, Kyouko, et al.
Publicado: (2019) -
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019) -
Cisplatin dose rate as a risk factor for nephrotoxicity in children.
por: Skinner, R., et al.
Publicado: (1998) -
The Effect of Different Colistin Dosing Regimens on Nephrotoxicity: A Cohort Study
por: Samarkos, Michael, et al.
Publicado: (2022) -
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol
por: Schaeffers, Anouk W. M. A., et al.
Publicado: (2023)